Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · market

Cancer biotech BlossomHill Therapeutics sets terms for $125 million IPO

3 August 2026 · By · Wire by Fusion42

Published

3 August 2026

Topic

market

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at renaissancecapital.com →

◆ Verified

Fusion42 · 3 August 2026 · Fusion42 review

BlossomHill Therapeutics, a biotech focused on small molecule cancer therapies, has announced terms for a $125 million IPO aimed at advancing its Phase 2-ready drug pipeline including treatments for EGFR-mutant non-small cell lung cancer and acute myeloid leukemia.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The IPO launch opens new funding pathways for cancer drug developers like you focused on tough mutations. You can now target partnerships or trials with clearer regulatory milestones on accelerated approvals.

◆ Coverage

1 source · 3 Aug 2026

◆ Related on Wire

◆ Topics

Biotechipocancer-biotechclinical-trialsfundraising